Market News & Trends
Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections
Peptilogics recently announced that the US FDA has granted Orphan Drug Designation for PLG0206, the company's first-in-class, broad-spectrum antibiotic peptide, for the treatment of prosthetic…
MilliporeSigma Announces $65-Million Antibody-Drug Conjugate Manufacturing Expansion
MilliporeSigma recently announced a $65-million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, WI. This investment will allow…
Catalent Invests $130 Million to Add Additional Manufacturing Capacity at its Gene Therapy Campus
Catalent recently announced it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans,…
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
RedHill Biopharma Ltd. recently announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro…
New Research Sheds Light on Multi-Organ Adverse Events From Immunotherapy
New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network adds important knowledge about how immunotherapy-related adverse events (irAEs)…
Liminal BioSciences Announces Resubmission of Biologics License Application
Liminal BioSciences Inc. recently announced the company, through its US subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for…
Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
Cynata Therapeutics Limited recently announced positive efficacy data from a study of its induced pluripotent stem cell (iPSC)-derived Cymerus mesenchymal stem cells (MSCs) in a…
Spero Therapeutics Announces Positive Topline Results From its Phase 3 ADAPT-PO Clinical Trial
Spero Therapeutics, Inc. recently announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero’s oral antibiotic candidate, tebipenem HBr, for the…
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic & Mucosal Immune Responses
Vaxart, Inc. recently announced pre-publication of a manuscript titled Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection. The manuscript describes the…
PhoreMost & XtalPi Sign AI-Based Collaboration Agreement
PhoreMost Limited and XtalPi Inc. recently announced they have entered into a drug discovery collaboration agreement…..
Exelixis & Catalent Enter Collaboration, License & Exclusive Option Agreement
Exelixis, Inc. and Catalent recently announced a partnership under which Catalent’s Redwood Bioscience subsidiary will develop multiple antibody-drug conjugates (ADCs) for….
AnGes & Brickell Biotech Announce Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19
AnGes, Inc. recently announced a collaboration agreement with Brickell Biotech, Inc. through which Brickell has the right to develop AnGes’ proprietary….
Evonik Qualifies Advanced Aseptic Filling Line for Complex Parenteral Drug Products
Evonik recently announced the qualification of an advanced aseptic filling line for complex parenteral drug products at its FDA-inspected Birmingham….
WEBINAR ALERT! - Solid Form Selection in Drug Development by AMRI
Dr. Steef Boerrigter, Senior Research Scientist, AMRI It’s important to consider the solid form of an API in the drug development process. Using the proper…
SGS Enrolls First Patient Into Biophytis COVA Clinical Study, a COVID-19 Related Acute Respiratory Failure Treatment Clinical Trial
SGS recently announce the enrollment of the first patient into an important new clinical trial designed to examine the safety, tolerability, and efficacy of….
Gilead Sciences & Jounce Therapeutics Announce Exclusive License Agreement
Gilead Sciences, Inc. recently announced an agreement with Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively…
Avomeen & Daré Bioscience Form Strategic Partnership to Accelerate Novel Pipeline
Avomeen and Daré Bioscience, Inc. recently announced the companies have signed an agreement under which Avomeen will provide….
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial
Alimera Sciences, Inc. recently announced it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to…
Chiasma Announces US Commercial Launch & Availability of the First & Only Oral Somatostatin Analog
Chiasma, Inc. recently announced the commercial launch and availability of MYCAPSSA (octreotide) capsules in the US for patients with acromegaly. MYCAPSSA, the first and only….
CorMedix Announces FDA Acceptance for Filing & Priority Review of NDA
CorMedix Inc. recently announced the US FDA has accepted for filing the company’s submitted New Drug Application (NDA) for Defencath, its product candidate to be…
